Antagonism of NMDA receptors as a potential treatment for Down syndrome: A pilot randomized controlled trial

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Boada, R ^a,b   Hutaff Lee, C ^b   Schrader, A ^b   Weitzenkamp, D ^c   Benke, T A ^a,b,d,e   Goldson, E J ^a,b   Costa, A C S ^d,e  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c Global Health and Health Disparities   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Alzheimer disease; Down syndrome; intellectual disability; memantine; trisomy 21; Ts65Dn

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

ADAPTIVE BEHAVIOR; ADULT; ANDROGENIC ALOPECIA; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DOWN SYNDROME; DRUG SAFETY; DRUG TOLERABILITY; ECHOLALIA; EPISODIC MEMORY; FEMALE; HAIR LOSS; HIPPOCAMPUS; HUMAN; LEARNING; MALE; MEMORY; NERVE CELL PLASTICITY; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SPATIAL MEMORY; TREATMENT DURATION; ADOLESCENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; DOWN SYNDROME; FEMALE; HUMANS; MALE; MEMANTINE; MEMORY, EPISODIC; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PROSPECTIVE STUDIES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84866076171     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.66     Document Type: Article

References (40)

1. Lejeune J, Turpin R, Gautier M. Le mongolism: premier exemple d'aberration autosomique humaine. Ann Genet 1959; 1: 1-49.
2. Patterson D, Costa AC. Down syndrome and genetics - a case of linked histories. Nat Rev Genet 2005; 6: 137-147. (Pubitemid 40179536)
3. Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE et al. National Birth Defects Prevention Network. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006.Birth Defects Res A Clin Mol Teratol 2010; 88: 1008-1016.
4. Pueschel SM, Hopmann MR. Speech and language abilities of children with Down syndrome: a parents's perspective. In: Kaiser AP, Gray DB (eds). Enhancing Children's Communication: Research Foundations for Intervention Communication and Language Intervention Series, vol. 2. P.H. Brookes: Baltimore, 1993 pp 335-362.
5. Carr J. Stability and change in cognitive ability over the life span: a comparison of populations with and without Down's syndrome. J Intellect Disabil Res 2005; 49: 915-928. (Pubitemid 43009345)
6. Turner S, Alborz A, Gayle V. Predictors of academic attainments of young people with Down's syndrome. J Intellect Disabil Res 2008; 52: 380-392. (Pubitemid 351560339)
7. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 2003; 74: 75-93. (Pubitemid 37244589)
8. Silverman W. Down syndrome: cognitive phenotype. Ment Retard Dev Disabil Res Rev 2007; 13: 228-236. (Pubitemid 47613277)
9. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 2010; 9: 623-633.
10. Edgin JO, Mason GM, Allman MJ, Capone GT, Deleon I, Maslen C et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome. J Neurodev Disord 2010; 2: 149-164.
11. Edgin JO, Kumar A, Spano G, Nadel L. Neuropsychological effects of second language exposure in Down syndrome. J Intellect Disabil Res 2011; 55: 351-356.
12. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003; 361: 1281-1289. (Pubitemid 36428586)
13. Zigman WB, Lott IT. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev 2007; 13: 237-246. (Pubitemid 47613278)
14. Costa AC. An assessment of the vestibulo-ocular reflex (VOR) in persons with Down syndrome. Exp Brain Res 2011; 214: 199-213.
15. Costa AC. An assessment of optokinetic nystagmus (OKN) in persons with Down syndrome. Exp Brain Res 2011; 214: 381-391.
16. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33: 1624-1632. (Pubitemid 351684704)
17. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2011; 221: 610-622.
18. Rueda N, Llorens-Martin M, Florez J, Valdizan E, Banerjee P, Trejo JL et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 2010; 21: 277-290.
19. Scott-McKean JJ, Costa AC. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem 2011; 18: 774-778.
20. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; : CD003154.
21. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother 2011; 12: 787-800.
22. Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother 2011; 11: 1359-1370.
23. Hodapp AF, Gerken KC. Correlations between scores for Peabody Picture Vocabulary Test-III and the Wechsler Intelligence Scale for Children-III. Psychol Rep 1999; 84: 1139-1142.
24. Costa AC. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci 2011; 33: 414-427.
25. Rabin LA, Barr WB, Burton LA. Assessment practices of clinical neuropsychologists in the United States and Canada: a survey of INS, NAN, and APA Division 40 members. Arch Clin Neuropsychol 2005; 20: 33-65. (Pubitemid 40029807)
26. Alexander MP, Stuss DT, Fansabedian N. California Verbal Learning Test: performance by patients with focal frontal and non-frontal lesions. Brain 2003; 126: 1493-1503. (Pubitemid 36644392)
27. Donders J. A confirmatory factor analysis of the California Verbal Learning Test-Second Edition (CVLT-II) in the standardization sample. Assessment 2008; 15: 123-131.
28. Reeves CB, Palmer SL, Reddick WE, Merchant TE, Buchanan GM, Gajjar A et al. Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol 2006; 31: 272-280.
29. Cherney LR, Halper AS. Performance on the California Verbal Learning Test following right hemisphere stroke: a longitudinal study. Top Stroke Rehabil 2007; 14: 21-25. (Pubitemid 46365383)
30. DeJong J, Donders J. A confirmatory factor analysis of the California Verbal Learning Test- Second Edition (CVLT-II) in a traumatic brain injury sample. Assessment 2009; 16: 328-336.
31. Lekeu F, Magis D, Marique P, Delbeuck X, Bechet S, Guillaume B et al. The California Verbal Learning Test and other standard clinical neuropsychological tests to predict conversion from mild memory impairment to dementia. J Clin Exp Neuropsychol 2010; 32: 164-173.
32. Quigg M, Broshek DK, Barbaro NM, Ward MM, Laxer KD, Yan G et al. Neuropsychological outcomes after Gamma Knife radiosurgery for mesial temporal lobe epilepsy: a prospective multicenter study. Epilepsia 2011; 52: 909-916.
33. Mesholam-Gately RI, Giuliano AJ, Zillmer EA, Barakat LP, Kumar A, Gur RC et al. Verbal learning and memory in older adults with minor and major depression. Arch Clin Neuropsychol 2012; 27: 196-207.
34. Johnsen GE, Asbjornsen AE. Consistent impaired verbal memory in PTSD: a metaanalysis. J Affect Disord 2008; 111: 74-82.
35. Albuquerque L, Loureiro C, Martins IP. Effect of lesion site on serial position during list learning: a study with the CVLT. Int J Neurosci 2008; 118: 917-933. (Pubitemid 351882620)
36. Lund J. Psychiatric aspects of Down's syndrome. Acta Psychiatr Scand 1988; 78: 369-374.
37. Capone GT, Grados MA, Kaufmann WE, Bernad-Ripoll S, Jewell A. Down syndrome and comorbid autism-spectrum disorder: characterization using the aberrant behavior checklist. Am J Med Genet A 2005; 134: 373-380. (Pubitemid 40613060)
38. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 528-536.
39. Costa AC. Alzheimer disease: treatment of Alzheimer disease in Down syndrome. Nat Rev Neurol 2012; 8: 182-184.
40. Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A 2010; 152A: 3028-3035.